PA3-17

· PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for PA3-17, covering 2025-12-05 to 2025-12-05. Get the full timeline:

Most recent: Clinical Trial Update: PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma [Phase 2]

See pricing